Key result
A half-dose (15 µg) BNT162b2 booster provided non-inferior immunogenicity compared to a standard dose (30 µg), with an anti-S-RBD IgG geometric mean ratio of 0.90 (95% CI 0.77-1.06) at day 14.
Why the study?
In the era of globally predominant omicron strains, a COVID-19 booster vaccine was needed, prompting evaluation of the immunogenicity of a half-dose BNT162b2 booster after AZD1222.
Does a half-dose BNT162b2 booster provide non-inferior immunogenicity compared to a standard dose in adults previously vaccinated with AZD1222?
Population
100 healthy adults aged 18-69 years who received two-dose AZD1222
Comparison
Half-dose (15 µg) vs standard-dose (30 µg) BNT162b2 booster
Design
Randomized clinical trial
Follow-up
90 days
Authors
Loading...
Supports half-dose BNT162b2 boosters for supply conservation; extends RCT evidence for fractional dosing after AZD1222 priming.
RCT (n=100)
randomized
Does a half-dose BNT162b2 booster provide non-inferior immunogenicity compared to a standard dose in adults previously vaccinated with AZD1222?
Effect estimate: GMR 0.90 (95% CI 0.77-1.06)
Absolute Event Rate: 2329.8% vs 2574.7%
A fractional low-dose BNT162b2 booster provides non-inferior immunogenicity compared to a standard dose, offering a dose-sparing strategy during vaccine shortages.
Nantanee et al. (2022) conducted an RCT in COVID-19 (n=100). BNT162b2 booster vs. 30 µg (standard dose) was evaluated on anti-S-RBD IgG at day 14 (BAU/mL) (GMR 0.90, 95% CI 0.77-1.06). A half-dose (15 µg) BNT162b2 booster provided non-inferior immunogenicity compared to a standard dose (30 µg), with an anti-S-RBD IgG geometric mean ratio of 0.90 (95% CI 0.77-1.06) at day 14.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: